Drugs / IVAC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05641545 | Oct 2022 → Sep 2024 | renal cell carcinoma | SLK Kliniken Heilbronn GmbH | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05641545 ↗ |
| Modality | Vaccine | “personalized peptide vaccine” NCT05641545 ↗ |